Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases

Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections

“…Similar results have been reported in a number of short-term studies (Avery et al 2006;Rich et al 2006;Spaide et al 2006;Yoganathan et al 2006;Aisenbrey et al 2007;Giansanti et al 2007;Lazic & Gabric 2007;Madhusudhana et al 2007;Weigert et al 2008). However, to date, only four other studies have reported 9-month and 12-month follow-up results (Arevalo et al 2008;Bashshur et al 2008;Cleary et al 2008;Fong et al 2008).…”

Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial

“…[11][12][13] Alternatively, most of the evidence supporting the use of bevacizumab for treatment of AMD is derived from interventional case series and retrospective studies. [23][24][25][26][27][28][29][30][31][32] Bevacizumab was formulated for intravenous use by its manufacturer, and at this time, its use in the eye is entirely off-label. Hindsight has shown in retrospective reviews, non-comparative case series, and international safety surveys that bevacizumab given intravitreally at 1.25 mg appears to be safe and non-toxic to the eye, with seemingly minimal systemic and ocular adverse effects.…”

Comparing outcomes in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration treated with two different doses of primary intravitreal bevacizumab: results of the pan-american collaborative retina study group (PACORES) at the 12-month follow-up

“…Promising outcomes of intravitreal bevacizumab in patients with CNV from AMD have been reported. [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29] Clinical experience with bevacizumab, as well as with other anti-VEGF agents, has shown that multiple injections are required to maintain the benefi ts of therapy. The great majority of studies have used 1.25-mg of bevacizumab, and all show a signifi cant, short-term decrease in macular thickness and improvement in visual acuity in a large number of patients.…”

“…12 Recent studies have demonstrated the promise of intravitreal injections of bevacizumab in the treatment of CNV secondary to AMD. [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29] All clinical experience to date has indicated that multiple injections of bevacizumab are required to maintain the benefi ts of therapy. [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29] However, the optimum dose and dosing sequence for intravitreal bevacizumab are still undetermined.…”